ABT Q3 2026 Earnings: EPS of $1.42 Narrowly Misses Consensus as Shares Slip - High Growth Earnings
ABT Q3 2026 Earnings: EPS of $1.42 Narrowly Misses Consensus as Shares Slip - High Growth Earnings https://www.dars.gov.et/
Covered in this story
What has happened since
- Abbott Laboratories is up 1.2% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 42 stories mentioning Abbott Laboratories, the earliest published 6 May 2017.
Summary aggregated from https://www.dars.gov.et/'s public RSS feed. The full reporting belongs to https://www.dars.gov.et/ — please read it on their site.